| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Azim Nejatizadeh | |
| Kianoosh Malekzadeh | |||
| Minoo Rajaei | |||
| Pooneh Nikuei | |||
| Nasrin Ghasemi | |||
| P2860 | cites work | Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia | Q73305965 |
| VEGF mRNA is unaltered in decidual and placental tissues in preeclampsia at delivery | Q73414919 | ||
| Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia | Q73506827 | ||
| Placenta growth factor is not an early marker for the development of severe preeclampsia | Q73873389 | ||
| Plasma placenta growth factor levels in midtrimester pregnancies | Q74567407 | ||
| Preeclampsia is associated with reduced serum levels of placenta growth factor | Q77690843 | ||
| Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences | Q79260245 | ||
| Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion | Q79685499 | ||
| Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia | Q79829262 | ||
| Placental ischemia and soluble fms-like tyrosine kinase 1: cause or consequence of preeclampsia? | Q80316215 | ||
| Expression of vascular endothelial growth factor receptor types 1, 2 and 3 in placenta from pregnancies complicated by hypertensive disorders | Q80547501 | ||
| Altered expression of angiogenesis-related placental genes in pre-eclampsia associated with intrauterine growth restriction | Q80580266 | ||
| Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia | Q81813556 | ||
| Circulating angiogenic proteins in trisomy 13 | Q82150298 | ||
| Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia | Q82875468 | ||
| Expression of VEGF receptors VEFGR-1 and VEGFR-2, angiopoietin receptors Tie-1 and Tie-2 in chorionic villi tree during early pregnancy | Q82938639 | ||
| Decreased expressions of vascular endothelial growth factor and visfatin in the placental bed of pregnancies complicated by preeclampsia | Q83547722 | ||
| Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study | Q84569501 | ||
| An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia | Q84768567 | ||
| Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor | Q24320710 | ||
| Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis | Q26825271 | ||
| Impaired adenosine-mediated angiogenesis in preeclampsia: potential implications for fetal programming | Q27024603 | ||
| Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2 | Q28221171 | ||
| Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR | Q28238949 | ||
| Hypertensive disorders of pregnancy | Q28239814 | ||
| Soluble endoglin contributes to the pathogenesis of preeclampsia | Q28244053 | ||
| Oxygen and placental villous development: origins of fetal hypoxia | Q28254162 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies | Q31843148 | ||
| Post-transcriptional control of expression of sFlt-1, an endogenous inhibitor of vascular endothelial growth factor | Q33206536 | ||
| Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta. | Q33290156 | ||
| Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry | Q33329370 | ||
| Molecular mechanisms of preeclampsia | Q33344105 | ||
| The genetic aspects of pre-eclampsia: achievements and limitations | Q33345506 | ||
| The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. | Q33755648 | ||
| Role of biomarkers in early detection of preeclampsia | Q33783531 | ||
| Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src | Q33871655 | ||
| The role of vascular endothelial growth factor in angiogenesis | Q34111713 | ||
| Evaluation the frequency of factor V Leiden mutation in pregnant women with preeclampsia syndrome in an Iranian population. | Q34176440 | ||
| Differential expression of Vegfr-2 and its soluble form in preeclampsia | Q34201006 | ||
| The vascular endothelial growth factor family in adverse pregnancy outcomes. | Q34267491 | ||
| Latest advances in understanding preeclampsia | Q34425288 | ||
| First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction | Q34647428 | ||
| Disrupted balance of angiogenic and antiangiogenic signalings in preeclampsia | Q34731047 | ||
| Involvement of Galectin-9/TIM-3 pathway in the systemic inflammatory response in early-onset preeclampsia | Q34927088 | ||
| Attenuation of VEGFR-2 expression by sFlt-1 and low oxygen in human placenta | Q35049491 | ||
| Expression and function of placenta growth factor: implications for abnormal placentation | Q35132174 | ||
| Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia | Q35145097 | ||
| Angiogenesis and vasculogenesis in pregnancy | Q35215691 | ||
| Comparative gene expression profiling of placentas from patients with severe pre-eclampsia and unexplained fetal growth restriction | Q35426799 | ||
| Circulating angiogenic factors and the risk of preeclampsia | Q47217679 | ||
| VEGF expression in the placenta from pregnancies complicated by hypertensive disorders | Q47339076 | ||
| Sequential expression of VEGF and its receptors in human placental villi during very early pregnancy: differences between placental vasculogenesis and angiogenesis. | Q47626896 | ||
| Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award | Q48348609 | ||
| Placental growth factor in the cerebrospinal fluid of women with preeclampsia. | Q48766370 | ||
| Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. | Q50779076 | ||
| Differential placental gene expression in severe preeclampsia. | Q51794890 | ||
| Soluble vascular endothelial growth factor receptor-1 (sFLT-1) mediates downregulation of FLT-1 and prevents activated neutrophils from women with preeclampsia from additional migration by VEGF. | Q52936000 | ||
| Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. | Q53538854 | ||
| Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. | Q53600812 | ||
| Differential expression profile of microRNAs in human placentas from preeclamptic pregnancies vs normal pregnancies. | Q54491050 | ||
| Placental expression of VEGF family mRNA in adverse pregnancy outcomes. | Q54525786 | ||
| Soluble and membranous vascular endothelial growth factor receptor-1 in pregnancies complicated by pre-eclampsia. | Q54789840 | ||
| Urinary Placental Growth Factor and Risk of Preeclampsia | Q56619498 | ||
| Soluble fms-Like Tyrosine Kinase 1 Is Increased in Preeclampsia But Not in Normotensive Pregnancies with Small-for-Gestational-Age Neonates: Relationship to Circulating Placental Growth Factor | Q56619503 | ||
| First Trimester Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 and Risk for Preeclampsia | Q56619507 | ||
| Whole-genome microarray and targeted analysis of angiogenesis-regulating gene expression (ENG, FLT1, VEGF, PlGF) in placentas from pre-eclamptic and small-for-gestational-age pregnancies | Q57248848 | ||
| Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction | Q57316937 | ||
| VEGF mRNA levels in placentae from pregnancies complicated by pre-eclampsia | Q61484906 | ||
| Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age | Q61845341 | ||
| Divergent trophoblast invasion and apoptosis in placental bed spiral arteries from pregnancies complicated by maternal anemia and early-onset preeclampsia/intrauterine growth restriction | Q61865458 | ||
| Maternal plasma VEGF, sVEGF-R1, and PlGF concentrations in preeclamptic and normotensive pregnant Zimbabwean women | Q62487968 | ||
| Colocalization of vascular endothelial growth factor (vascular permeability factor) and insulin in pancreatic islet cells | Q71825682 | ||
| Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia | Q73078525 | ||
| Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy | Q35699115 | ||
| Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies | Q35764454 | ||
| Placental-related diseases of pregnancy: Involvement of oxidative stress and implications in human evolution | Q35810254 | ||
| Angiogenic imbalance in the pathophysiology of preeclampsia: newer insights | Q35941009 | ||
| Second trimester anti-angiogenic proteins and preeclampsia | Q36034224 | ||
| Preeclampsia up-regulates angiogenesis-associated microRNA (i.e., miR-17, -20a, and -20b) that target ephrin-B2 and EPHB4 in human placenta | Q36069875 | ||
| Epigenetics and microRNAs in preeclampsia | Q36103371 | ||
| A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia | Q36189562 | ||
| Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia | Q36288766 | ||
| Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis | Q36335555 | ||
| New insights into the biology of preeclampsia | Q36371864 | ||
| Angiogenic factors in preeclampsia and related disorders | Q36526596 | ||
| Pre-eclampsia in pregnancy and subsequent risk for breast cancer | Q36624347 | ||
| MicroRNAs in Human Placental Development and Pregnancy Complications | Q36790358 | ||
| Vasculogenesis and angiogenesis in the early human placenta | Q36851553 | ||
| A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a sma | Q36984261 | ||
| Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia | Q37221219 | ||
| Prediction and prevention of recurrent preeclampsia | Q37231387 | ||
| Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? | Q37366512 | ||
| Prenatal Clinical Assessment of sFlt-1 (Soluble fms-like Tyrosine Kinase-1)/PlGF (Placental Growth Factor) Ratio as a Diagnostic Tool for Preeclampsia, Pregnancy-induced Hypertension, and Proteinuria | Q37395519 | ||
| The global impact of pre-eclampsia and eclampsia | Q37493240 | ||
| Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. | Q37502702 | ||
| Preeclampsia: the role of angiogenic factors in its pathogenesis | Q37512886 | ||
| The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application | Q37748188 | ||
| Genetic variants in pre-eclampsia: a meta-analysis. | Q39489329 | ||
| Differential expression of VE-cadherin and VEGFR2 in placental syncytiotrophoblast during preeclampsia - New perspectives to explain the pathophysiology | Q39737754 | ||
| The expression of VEGF receptor genes is concurrently influenced by epigenetic gene silencing of the genes and VEGF activation | Q39820548 | ||
| Second-trimester angiogenic factors as biomarkers for future-onset preeclampsia | Q40184951 | ||
| Influence of hypoxia on vascular endothelial growth factor and chorionic gonadotrophin production in the trophoblast-derived cell lines: JEG, JAr and BeWo | Q41101465 | ||
| Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium | Q41250498 | ||
| Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. | Q42816830 | ||
| Cytokine-related genes and oxidation-related genes detected in preeclamptic placentas | Q43269905 | ||
| Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. | Q43592482 | ||
| Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies | Q43991495 | ||
| Hypoxia-reoxygenation: a potent inducer of apoptotic changes in the human placenta and possible etiological factor in preeclampsia. | Q44044678 | ||
| Placental bed biopsies in placental abruption | Q45914319 | ||
| First trimester urinary placental growth factor and development of pre-eclampsia. | Q46120674 | ||
| Quantitative analysis of trophoblast invasion in preeclampsia | Q46211995 | ||
| Prediction of preeclampsia with maternal mid-trimester placental growth factor, activin A, fibronectin and uterine artery Doppler velocimetry | Q46512653 | ||
| A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib | Q46757524 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pre-eclampsia | Q61335 |
| angiogenesis inhibitor | Q574834 | ||
| biomarker | Q864574 | ||
| P304 | page(s) | 251-262 | |
| P577 | publication date | 2015-05-01 | |
| P1433 | published in | Iranian journal of reproductive medicine Yazd Research & Clinical Centre for Infertility | Q26842009 |
| P1476 | title | The imbalance in expression of angiogenic and anti-angiogenic factors as candidate predictive biomarker in preeclampsia | |
| P478 | volume | 13 |
| Q47836788 | Cadmium inhibits placental trophoblast cell migration via miRNA regulation of the transforming growth factor beta (TGF-β) pathway. |
| Q56996369 | Disruption in the Regulation of Immune Responses in the Placental Subtype of Preeclampsia |
| Q92909980 | Evaluation of Placental VEGFA mRNA Expression in Preeclampsia: A Case Control Study |
| Q47980162 | Hypoxia downregulates the angiogenesis in human placenta via Notch1 signaling pathway |
| Q92580237 | Transcriptome analysis of the effect of pyrroloquinoline quinone disodium (PQQ·Na2) on reproductive performance in sows during gestation and lactation |
| Q28396485 | miRNAs as common regulators of the transforming growth factor (TGF)-β pathway in the preeclamptic placenta and cadmium-treated trophoblasts: Links between the environment, the epigenome and preeclampsia |
Search more.